伊沙佐米临床药理学:首个口服蛋白酶体抑制剂
伊沙佐米是首个口服蛋白酶体抑制剂,与来那度胺和地塞米松联合用于既往接受过至少一种治疗的多发性骨髓瘤患者。本文综述其药理学特征,包括快速吸收、线性药代动力学、高脂餐影响吸收、特定人群剂量调整及药物相互作用。
要点
- 高脂餐降低伊沙佐米吸收速率和程度,建议空腹服用。
- 严重肾功能损害、需透析的终末期肾病或中重度肝损害患者起始剂量降至3mg。
- 避免与强CYP3A诱导剂(如利福平)联用;强CYP3A抑制剂无显著影响。
核心结论
- 伊沙佐米药代动力学特征支持其口服给药,特定人群需调整剂量,应避免与强CYP3A诱导剂联用。
研究设计与样本
- 综述性文章,汇总伊沙佐米临床药理学研究数据。
主要发现
- 伊沙佐米吸收迅速,中位达峰时间约1小时,口服生物利用度58%,终末半衰期9.5天。
- 血浆暴露随剂量成比例增加。
- 高脂餐降低吸收速率和程度。
- 群体药代动力学分析显示年龄、体重、种族、性别、轻中度肾损害或轻度肝损害无需调整剂量。
关键数值与推荐
- 严重肾损害、需透析的终末期肾病或中重度肝损害患者起始剂量从4mg降至3mg。
- 强CYP3A诱导剂利福平导致伊沙佐米暴露临床相关降低,建议避免联用。
- III期TOURMALINE-MM1研究暴露-反应分析支持每周4mg(每28天周期第1、8、15天)的获批剂量方案具有良好获益-风险特征。
临床怎么用
- 伊沙佐米应空腹服用,避免与强CYP3A诱导剂联用。
- 严重肾损害、需透析的终末期肾病或中重度肝损害患者起始剂量降至3mg。
- 轻中度肾损害或轻度肝损害、年龄、体重、种族、性别无需调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and preferentially binds to and inhibits the β5 chymotrypsin-like proteolytic site. Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose. Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%). Plasma exposures of ixazomib increase in a dose-proportional manner. A high-fat meal decreases both the rate and extent of ixazomib absorption, supporting administration on an empty stomach. Population PK analyses demonstrated that no dose adjustment is required based on age, body size/weight, race, sex, mild-to-moderate renal impairment, or mild hepatic impairment. Results from dedicated studies indicate that a reduced starting dose (from 4 to 3 mg) is appropriate for patients with severe renal impairment, end-stage renal disease requiring dialysis, or moderate-to-severe hepatic impairment. Non-cytochrome P450 (CYP)-mediated metabolism appears to be the major clearance mechanism for ixazomib. Drug-drug interaction studies have shown no meaningful effects of strong inhibitors of CYP3A on ixazomib PK; however, the strong inducer rifampin caused a clinically relevant reduction in ixazomib exposure, supporting the recommendation to avoid concomitant administration of ixazomib with strong CYP3A inducers. Exposure-response analyses of data from the phase III TOURMALINE-MM1 registrational study demonstrate a favorable benefit-risk profile for the approved dose and regimen of weekly ixazomib 4 mg on days 1, 8, and 15 of each 28-day cycle.
引用
- Gupta N, Hanley MJ, Xia C, et al. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clin Pharmacokinet. 2019. PMID: 30117017. doi:10.1007/s40262-018-0702-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。